Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Beyond Air ( (XAIR) ) just unveiled an announcement.
On November 4, 2025, Beyond Air, Inc. entered into financing agreements with Streeterville Capital, securing up to $32 million in potential proceeds. This includes a $12 million promissory note and a $20 million equity line of credit. The financing aims to accelerate the company’s commercial expansion, particularly for its LungFit PH product, and potentially achieve profitability. The agreements provide flexibility for Beyond Air to enhance its operations and strategic initiatives, extending its cash runway into 2027.
The most recent analyst rating on (XAIR) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.
Spark’s Take on XAIR Stock
According to Spark, TipRanks’ AI Analyst, XAIR is a Neutral.
Beyond Air’s overall stock score reflects significant financial challenges despite strong revenue growth. The company’s financial performance is hindered by negative profitability and cash flow issues, which are the most significant factors impacting the score. Technical analysis indicates bearish momentum, further weighing on the stock. While the earnings call provided some positive insights, ongoing net losses and valuation concerns limit the overall score.
To see Spark’s full report on XAIR stock, click here.
More about Beyond Air
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company that focuses on harnessing the power of nitric oxide (NO) to improve the lives of patients with respiratory illnesses, neurological disorders, and solid tumors. The company has received FDA approval and CE Mark for its LungFit PH system, which treats neonates with hypoxic respiratory failure, and is advancing other LungFit systems in clinical trials for severe lung infections.
Average Trading Volume: 2,929,725
Technical Sentiment Signal: Strong Sell
Current Market Cap: $14.76M
For a thorough assessment of XAIR stock, go to TipRanks’ Stock Analysis page.